Hokkaido University · Medicine
Hirofumi Sawa 교수의 연구실은 바이러스의 감염 메커니즘과 항바이러스 치료제 개발을 중심으로 연구를 진행하고 있습니다. 특히 JC 바이러스의 수용체 규명과 SARS-CoV-2의 주요 단백질을 타겟으로 한 구강 투여 가능한 항바이러스 제제(예: 엔시트렐비르)의 개발에 초점을 맞추고 있습니다. 연구는 바이러스의 세포 침입 메커니즘 이해와 동시에 임상적 적용이 가능한 약물 후보 물질의 선별 및 특성 분석을 포함합니다.
Figures are computed from collected data and may differ slightly.
JC virus (JCV) belongs to the polyomavirus family of double-stranded DNA viruses and in humans causes a demyelinating disease of the central nervous system, progressive multifocal leukoencephalopathy. Its hemagglutination activity and entry into host cells have been reported to depend on an N-linked glycoprotein containing sialic acid. In order to identify the receptors of JCV, we generated virus-like particles (VLP) consisting of major viral capsid protein VP1. We then developed an indirect VLP
In parallel with vaccination, oral antiviral agents are highly anticipated to act as countermeasures for the treatment of the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Oral antiviral medication demands not only high antiviral activity but also target specificity, favorable oral bioavailability, and high metabolic stability. Although a large number of compounds have been identified as potential inhibitors of SARS-CoV-2 inf
Open papers in the app to read, cite, and organize with AI.
